• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Life Sciences | News, Analysis, Insights - HIT Consultant

GenapSys Nabs $90M to Commercialize Its Breakthrough Electronic Gene Sequencer

by Fred Pennic 11/20/2019 Leave a Comment

- GenapSys launches their first-of-its-kind electronic gene sequencer as well as the completion of a $90M series C funding round led by top biotech investor Foresite Capital. - GenapSys is the first & only to use direct electronic sequencing -- this allows for a simpler workflow, dramatically reduced costs, turnaround time and device size. - The GenapSys Sequencer is exceptionally accurate and 100x smaller and more affordable than current high-throughput sequencers and will significantly expand access to genetic health insights. GenapSys Inc. announced today that it has completed a $90 million funding round, led by Foresite Capital to commercialize the smallest and most affordable highly accurate sequencer ever developed. Now available for purchase, the device uses first-of-its-kind technology to deliver results at a fraction of the cost of legacy technologies, while still delivering highly accurate results. This latest investment round brings the company’s total funding to $166M to date. The new capital will be used to drive the commercial launch of the company’s first-generation product, grow GenapSys’ interdisciplinary team, and empower continued innovation. Accessible Sequencing Holds the Key to Innovation In 2019, 10 million people will die of cancer. And, yet, only 3 percent of cancer drugs tested in clinical trials since 2000 have been approved for patient use and not a single one offers a cure. Gene sequencing maybe the answer. By analyzing every component of our DNA, gene sequencing allows doctors and scientists to more effectively diagnose disease and develop better treatments. Beyond cancer, sequencing has the potential to supercharge everything from reproductive health to pathogen testing. But a single sequencing device typically costs up to $1M, limiting its reach and acting as a major bottleneck to advancement in healthcare. A Breakthrough in Sequencing with High Accuracy and Low Cost GenapSys is the first & only to use direct electronic sequencing -- this allows for a simpler workflow, dramatically reduced costs, turnaround time and device size miniaturized to the size of an iPad. It's up to 100x smaller and less expensive at under $10,000 than legacy sequencing technologies, while redefining the gold standard with over 99.9% accuracy. In other words, similar to the iPhone, sequencing will be taken to the size of a mobile device and made affordable to nearly any institution. For the $46B genomics market previously dominated by much more expensive device companies like Illumina, this could transform healthcare as we know it. Unlike many others on the market, GenapSys achieves gold standard accuracy while maintaining low costs and portability. An independent study conducted by The Jackson Laboratory, a leading global nonprofit biomedical research institution, found that GenapSys sequencers deliver consistent and excellent performance across a variety of biological samples. Recently at American Society of Human Genetics in Houston, The Jackson Laboratory presented the results of their study which found that the GenapSys sequencers are superior to optical detection methods in detecting single nucleotide mutations, a critical task used for cancer and inherited disease detection. Availability The GenapSys sequencer has been tested extensively across leading genomics labs across the nation. All studies thus far have indicated exceptional performance; published work is publicly available on BioRxiv. The GenapSys Sequencer is currently available for order in the U.S. with global sales beginning in early 2020. “We are entering a multi-decade era of genomics that will revolutionize many industries, including healthcare diagnostics, pharmaceutical discovery, personalized medicine, food testing, forensics, agriculture, biology and beyond - but until now, we’ve lacked the access necessary to realize this potential,” explained Dr. Hesaam Esfandyarpour, CEO and founder of GenapSys. “With our new sequencer, we can rapidly enable and scale genomics power to every researcher, physician, provider, and patient around the world.”

- GenapSys launches first-of-its-kind electronic gene sequencer as well as the completion of a $90M series C funding round led by top biotech investor Foresite Capital.  - GenapSys is the first & only to use direct electronic sequencing -- this allows for a simpler workflow, dramatically reduced costs, turnaround time and device size.- The GenapSys Sequencer is exceptionally accurate and 100x smaller and more affordable than current high-throughput sequencers and will significantly expand
Read More

InterSystems, Virtusa Partner to Enhance Patient Data Integration

by Jasmine Pennic 11/20/2019 Leave a Comment

InterSystems, Virtusa Partner to Enhance Patient Data Integration

- InterSystems and Virtusa Corporation partner to enhance the healthcare data integration capabilities of its vLife™ life sciences platform.- The Collaboration will create an advanced platform for healthcare data management, research and analytics.InterSystems, and Virtusa Corporation, a global provider of digital strategy, digital engineering, and IT services and solutions have announced their partnership in an effort to drive positive patient outcomes while reducing cost through improved
Read More

Life Image, Graticule Launches Imaging Dataset In AWS Data Exchange

by Fred Pennic 11/18/2019 Leave a Comment

Life Image, Graticule Launches Imaging Dataset In AWS Data Exchange

 - Life Image and Graticule announced the availability of GLIMPS (Graticule Life Image Machine Parsed Set) data licensing subscriptions in AWS Data Exchange. - GLIMPS (Graticule Life Image Machine Parsed Set) is a de-identified patient-level data set including a summary of features generated from NLP processing on Life Image data. - The goal of GLIMPS is to provide a cost-effective patient-level snapshot to biopharma data science teams to fuel the necessary discussions about these data, leading
Read More

Five Lessons Learned From Building A CRM for Pharma

by Thom Doyle, President, Human Care Systems 11/15/2019 Leave a Comment

Five Lessons Learned From Building a CRM for Pharma

We all know the pleasure of interacting with technology that does exactly what it’s designed to do. Whether it’s getting to your destination via Waze, reserving dinner through OpenTable or making an electronic payment through Venmo, applications that work have one important thing in common: they are designed with a purpose and are the true experts in getting exactly that thing done seamlessly. But professional industry software, especially when it comes to healthcare, is a lot more complex.
Read More

Vermont Health Network Launches Pilot Project to Offer Free Genetic DNA Testing

by Fred Pennic 11/07/2019 Leave a Comment

Vermont Health Network Launches Pilot Project to Offer Free Genetic DNA Testing

Key Highlights LunaPBC announces a partnership allowing patients in Vermont to donate genetic information to medical research via a partnership with the University of Vermont Health Network via Invitae. Free genetic testing is now offered to qualifying patients to identify increased risk for certain diseases. Patients can then consent to securely share their data with researchers through the LunaDNA platform. In return, patients receive shares of ownership in the company, allowing
Read More

Mission Bio Expands Into Single-Cell Multi-Omics With Platform That Detects DNA and Protein from the Same Cell

by Fred Pennic 11/06/2019 Leave a Comment

Mission Bio Expands Into Single-Cell Multi-Omics With Platform That Detects DNA and Protein from the Same Cell

Key Highlights- Mission Bio expands into single-cell multi-omics with the launch of its new proprietary technology platform. - The Tapestri Platform is the first and only to enable key insights to drive the development of more impactful cancer therapies. Mission Bio, Inc., a South San Francisco, CA-based pioneer in high-throughput single-cell DNA analysis and precision genomics, today announced its expansion into single-cell multi-omics. The company’s proprietary technology, the Tapestri
Read More

Aetion, IBM Watson Health Co-Develop Solution for Conducting Regulatory-Grade RWE Analysis

by Jasmine Pennic 11/04/2019 Leave a Comment

Aetion, IBM Watson Health Co-Develop Solution for Conducting Regulatory-Grade RWE Analysis

- IBM Watson Health and Aetion will combine the Aetion Evidence Platform with IBM MarketScan data to provide a turn-key solution for conducting regulatory-grade RWE analysis. - The partnership will satisfy mid-market companies’ demand to streamline the drug R&D process and will allow RWE to play a much greater role in support of companies’ drug portfolios. RWE can enable researchers to supplement clinical trials by optimizing the development of treatments, determining new indications for
Read More

3 Myths About Robotic Process Automation in Healthcare, Debunked

by Jason Warrelmann, Global Director of Healthcare and Life Sciences, UiPath 10/28/2019 Leave a Comment

3 Myths About Robotic Process Automation in Healthcare, Debunked

Patients’ wellbeing should be the central focus of healthcare. Unfortunately, this isn’t always the case. Studies show that doctors spend almost half their time on data entry and more than half of their workdays managing records instead of caring for patients. Add this lost time to the fact that healthcare in the United States is already understaffed – averaging 2.5 healthcare practitioners to every 1,000 patients – and it’s easy to see that something’s got to give to bring
Read More

Healx Nabs $56M to Expand AI-Driven Drug Discovery Platform for Rare Diseases

by Jasmine Pennic 10/16/2019 Leave a Comment

Healx Nabs $56M to Expand AI-Driven Drug Discovery Platform for Rare Diseases

- UK startup Healx lands $56M, led by Atomico to build an AI-driven clinical-stage portfolio for rare diseases, including treatments for fragile X syndrome, the leading genetic cause of autism. - Healx’s Rare Treatment Accelerator program is a new initiative launched in close partnership with patient communities to identify clinic-ready treatments for rare diseases within 24 months. Healx, a Cambridge, England-based AI-powered and patient-inspired technology company specializing in
Read More

McKesson, Aetion Partner on Real-World Evidence (RWE) in Cancer Research

by Jasmine Pennic 10/15/2019 Leave a Comment

Google Cancer Research

- Aetion and McKesson announced a strategic collaboration focused on advancing the use of real-world evidence (RWE) in cancer research. - Relationship pairs Aetion Evidence Platform and McKesson’s robust oncology data sets to accelerate regulatory-grade oncology studiesAetion and McKesson, today announced a strategic collaboration focused on advancing the use of real-world evidence (RWE) in cancer research to benefit patients, regulators, the biopharma industry, and payers. The partnership will
Read More

  • Previous Page
  • Go to page 1
  • Interim pages omitted …
  • Go to page 81
  • Go to page 82
  • Go to page 83
  • Go to page 84
  • Go to page 85
  • Go to page 86
  • Next Page

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Virta Health CEO: GLP-1s Didn’t Kill Weight Watchers, Its Broken Model Did

Most-Read

Moving Beyond EHRs: What Lies Ahead for Healthcare Digitization?

AI Agents vs. Chatbots: Understanding Agentic AI’s Role in Healthcare

AI Breakthrough Reveals 2025 AI Breakthrough Award Winners

AI Breakthrough Reveals 2025 AI Breakthrough Award Winners

Healthcare's Big Blind Spot: The Measurement Crisis in Inpatient Psychiatry

Healthcare’s Big Blind Spot: The Measurement Crisis in Inpatient Psychiatry

Lessons Learned from The Change Healthcare Cyberattack, One Year Later

Lessons Learned from The Change Healthcare Cyberattack, One Year Later

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Omada Health Launches "Nutritional Intelligence" with AI Agent OmadaSpark

Omada Health Soars in NASDAQ Debut, Signaling Digital Health IPO Rebound

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |